



RECEIVED

APR 1 2002

TECH CENTER 1600/2900

OBLON

SPIVAK

McCLELLAND

MAIER

&

NEUSTADT

P.C.

ATTORNEYS AT LAW

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RE: Application Serial No.: 09/831,907

Applicants: Jean-Claude BEAUVILLAIN, et al.

Filing Date: September 18, 2001

For: MAMMALIAN UROTENSINS II
AND APPLICATIONS THEREOF

Group Art Unit: 1636

Examiner: Sita S. Pappu

SIR:

Attached hereto for filing are the following papers:

Preliminary Amendment w/Marked Up Copy (5 pp.)

Substitute Sequence Listing Paper (21 pp.)

Substitute Sequence Listing Computer Readable Form (CRF) Diskette

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Attorney of Record
Registration No. 24,618



22850

James J. Kelly, Ph.D.
Registration No. 41,504

(703) 413-3000 (phone)
(703) 413-2220 (fax)



UNITED STATES PATENT AND TRADEMARK OFFICE

27 2002
JC16

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/831,907	09/18/2001	Jean-Claude Beauvillain	20888USOPCT	3062

22850 7590 02/25/2002

OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC
FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

FEB 28 2002

OBLON, SPIVAK, MCCLELLAND,
MAIER & NEUSTADT, P.C.

EXAMINER

PAPPU, SITA S

ART UNIT	PAPER NUMBER
1636	8

DATE MAILED: 02/25/2002

Seq 1st One

3-27-02

Please find below and/or attached an Office communication concerning this application or proceeding.

RCM
3-1-02



Applicants

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/831,907	09/18/2001	Beauvillain, J-C.	208888USOPCT

EXAMINER	
Sita S. Pappu	
ART UNIT	PAPER NUMBER
1636	8

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APR - 1 2002

TECH CENTER 1600/2900

Sequences are disclosed in the specification but are not identified by their sequence identifiers (i.e. SEQ ID NO). For example, claims 1, 9; abstract on page 21; specification on page 2, lines 31-32 recite a heptapeptide sequence and Figures 1-4 and 6 depict nucleotide and amino acid sequences that are not identified by sequence identifier in either the Figure or the Brief Description of the Drawings. Applicant is further reminded that amendment to the specification, and/or figures is required to comply with 37 C.F.R. 1.821(d). Each sequence disclosed in the specification and figures must be identified by its sequence identifier (i.e., SEQ ID NO:). Since the specification discloses sequences that are not identified by their sequence identifier, it is unclear if all disclosed sequences are included in the sequence listing. Applicant is advised that, a substitute CRF and paper copy of the Sequence Listing are required only if the sequences are not already included in the Sequence Listing. Applicant is reminded that the entire specification and figures should be reviewed for sequence disclosures.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Sita S. Pappu whose telephone number is (703) 305-5039. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Irem Yucel whose telephone number is (703) 305-1998. The fax number for the organization where this application is assigned is (703) 308-8724. Any inquiry of a general nature or relating to the status of this application should be directed to the Patent Analyst at (703) 305-2982.

Anne-Marie Baker
ANNE-MARIE BAKER
PATENT EXAMINER